Biotech Values

[ghmm]

HCV:

Very impressive (efficacy with such a low dose), I guess since their early setback they've done quite well at coming up with other compounds. I'ld be curious to see if the AE is a fluke or turns out to be a real signal. It seems the bar gets higher and higher at each conference for HCV compounds which is good for patients bad for investors IMO. Well I certainly can't predict who (if any) will dominate the market and for how short a period before one of the compounds in the mix is replaced.